Skip to content
VIR·Nasdaq·US

Vir Biotechnology

Vir Biotechnology is a clinical-stage biopharmaceutical company that discovers and develops medicines for serious infectious diseases and cancer. Its clinical pipeline targets hepatitis delta virus and multiple solid tumors, and it develops the programs using its antibody discovery and engineering platforms, including dAIsY and PRO-XTEN.

Source: SEC 10-K Feb 23, 2026

Thematic Position

VIR

Relationship Groups

Suppliers1
Partners3
Licensing4
Competitors12

Relationship details are part of the Pro plan.

Ended Relationships

6 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

patent limitationsgeopolitical conflict
Russian Federation limitations on patents originating from countries supporting Ukraine, including the United States
SEC 10-QMay 7, 2026

The full regulatory passage is part of the Pro plan.

1 more · Regulatory and geopolitical insights are part of the Pro plan.